1106: EDIT-202, a Multiplexed CRISPR-Cas12a Gene-Edited iPSC-Derived NK Cell Therapy Has Prolonged Persistence, Promotes High Cytotoxicity, and Enhances In Vivo Tumor Killing https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=2005
831: SLEEK: A Method for Highly Efficient Knock-in and Expression of Transgene Cargos for Next-generation Cell-based Medicines https://annualmeeting.asgct.org/abstracts/abstract-details?abstractId=1751
AsCas12a gene-edited iPSC-derived NK cells constitutively expressing CD16 and membrane-bound IL-15 demonstrate prolonged persistence and robust anti-tumor activities in a solid tumor mouse model https://www.abstractsonline.com/pp8/#!/10517/presentation/16690
ASH PR https://www.globenewswire.com/news-release/2021/12/12/2350352/0/en/Editas-Medicine-Reports-Preclinical-Data-Demonstrating-Robust-Tumor-Reduction-and-Clearance-Using-Novel-Engineered-iNK-Cells-at-the-American-Society-of-Hematology-Annual-Meeting.html
From the PR: In these experiments, iPSCs were edited using the Company’s SLEEK gene editing technology at the GAPDH locus with a proprietary, Editas-engineered AsCas12a nuclease to knock-in high-affinity CD16 and membrane bound IL-15. iPSC clones were then differentiated into iNKs that were confirmed to express high levels of CD16 and IL-15. Increasing NK cell CD16 expression can improve anti-tumour activity when combined with antibody-dependent cell-mediated cytotoxicity (ADCC)-enabling antibodies. IL-15 is important for NK cell survival, and increasing IL-15 expression prolongs the persistence of NK cells. Knock-in of IL-15 may also eliminate the need to administer cytokines systemically, which can cause severe toxicity.
Results demonstrated that the edited iNK cells exhibited enhanced serial tumour cell killing through ADCC in a2D assay against SKOV-3 ovarian cancer cells and in a 3D tumour spheroid killing assay. The edited iNK cells were also able to persist for a dramatically longer period of time relative to unedited iNK cells. Together, these data provide strong support for the continued development of engineered iPSC derived iNK cells as a potential novel class of therapeutics targeting solid tumours.
''In this promising new research, we demonstrate the use of our proprietary SLEEK technology to knock-in both CD16 and IL-15 into iNK cells. The engineered cells demonstrated potent anti-tumour activity and substantially increased persistence without systemic cytokines, an important limitation with many existing NK cell approaches. We also believe this to be a potentially safer and more reliable approach to developing next generation NK cell therapy medicines because through our iPSC development process, we only select cell clones that have exactly the desired on-target edits, thereby avoiding the possibility of cell abnormalities being introduced,'' said Mark S. Shearman, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. ''NK cells are great candidates for off-the-shelf immunotherapy medicines given their high tumour killing capacity and their low propensity for graft-versus-host disease, and we believe these data provide evidence for the potential of future experimental medicines from our iNK program to exert enhanced anti-tumour activity in the clinic in the treatment of solid tumours.''
Deletion of CISH and TGFßR2 in iPSC-Derived NK Cells Promotes High Cytotoxicity and Enhances In Vivo Tumor Killing https://ash.confex.com/ash/2021/webprogram/Paper150731.html
Preclinical Development of EDIT301, an Autologous Cell Therapy Comprising AsCas12a-RNP Modified Mobilized Peripheral Blood-CD34+ Cells for the Potential Treatment of Transfusion Dependent Beta Thalassemia https://ash.confex.com/ash/2021/webprogram/Paper149956.html
GRTS and EDIT Biotech Stock Plays Update | Big Events Coming Up!
I chat about some recent events and news with Gritstone ($GRTS) and Editas ($EDIT) - two very exciting biotechnology companies doing work in a variety of treatments like immunotherapy & gene editing.
Watch on YouTube
Initial clinical data for 101 is planned later this month. The data will include patient safety assessments and a preliminary analysis of secondary endpoints relating to signals of gene editing and clinical benefit. The presentation will cover cumulative data from patients in the adult low-dose and mid-dose cohorts. As required by the trial protocol, all patients are monitored every three months for the first year and at various timepoints for another two years.
Editas ($EDIT) has a Big Event Coming Up! | Gene Editing Biotech
Editas ($EDIT) has got a big event on September 27th, and I decided to ride the wave and share my thoughts as to why. Events are king in biotechs. Tell us what you think about our new series! Is this the kind if info you would be looking for? What other DD should we add?
Watch the Video on Youtube
Thank you for the explanation and your time. Have a good weekend.
Cancer is highly complex, so multiplexed gene editing will be needed to generate better cell therapies. One of the benefits of CRISPR is the ability to knockout multiple genes with (very) high efficacy, but that has not been the case for knock-ins. Now with this approach, it seems to have been overcome. If you take HLA-E, the efficacy (for knock-in) was over 88%, and this should 'shield' the majority of cells from being rejected by the patient they would be given to. ADAP will use the same approach for its iPSC-derived TCR-T cell therapies https://www.nature.com/articles/nbt.3860
Wow that sounds so?? What the heck does any of that mean?
''New preclinical data demonstrated that SLEEK results in the knock-in of multiple clinically relevant transgenes through a proprietary process that selects for cells containing the knock-in cargo. In addition, high percentage knock-in efficiencies were enabled by Editas Medicine’s proprietary engineered AsCas12a nuclease. More than 90 percent knock-in efficiencies were observed in various clinically relevant target cells, including iPSCs, T cells, and NK cells. Additionally, SLEEK may be used to fine-tune the expression levels of transgene cargos, an important attribute of next-generation cell therapy medicines.'' https://www.globenewswire.com/news-release/2021/08/20/2284285/0/en/Editas-Medicine-Presents-Data-on-New-SLEEK-Gene-Editing-Technology-at-Cold-Spring-Harbor-Laboratory-s-Genome-Engineering-CRISPR-Frontiers-Meeting.html
Not sure what happened in the last hour, but the genomic stocks have all exploded upwards! EDIT is up 21% today. CRSP AND NTLA are making similar moves. I don’t know what triggered it, but good news for sure.
For sure! I've been in NTLA, EDIT and ARCT for a while just waiting for the CRSPR-Cas9 technology to be shown to be effective. We're just about there. If they don't explode in 2021, we should see it in 2022 the latest with all of the potentially great results from this technology!
Genome Stocks-Gene Editing.
$BEAM 5 billion market cap ARKG ETD
$EDIT 5.1 billion market cap ARKG ETF
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders ARKG ETF
edit Looking for a $100.00 floor soon this stock is a beast along with beam. HGEN looks great too most people don't know they are a gene editing angle to there company besides monoclonal antibodies platform space which is being gobbled up by big pharma
$EDIT 5.2 Billion market cap
$Beam 5.5 market cap
$HGEN 800 million market cap phase 3 CV-19
Yes, no sympathy for the short sellers, but I love them for the profits they are bringing to us.
Good call on the Short Squeeze. I've been following EDIT for a while and with no news on EDIT-101 or EDIT-301, the Shorts may be the driving force behind the price run up right now. As of about a month ago, about 18% of shares were short. Not a great place to be! And frankly, I don't have a lot of sympathy....
CRSPR stocks are hot indeed! This continued price explosion in EDIT could be influenced by:
1. Work in sickle cell disease
2. Progress in hereditary blindness. Block buster news soon?
3. Short squeeze???
4. Any buyout rumors?
I have been on this stock for a while and took profits on calls way too early. I’m going to hold this stock. This technology will lead to a $500 or $1000 stock in the future.
It looks like EDIT has become stock of the year. It took a while but was worth holding. I have sold only a few shares for profit and expect to hold on for now anticipating 500% upside in next few years. Options have also paid out handsomely . I looked at buying more May $60 calls but the premium seemed too high.
Robust Pre-Clinical Results and Large-Scale Manufacturing Process for EDIT-301: An Autologous Cell Therapy for the Potential Treatment of SCD https://www.editasmedicine.com/wp-content/uploads/2020/12/EDIT-301-ASH-Poster.pdf
Preclinical Development of EDIT-201, a Multigene Edited Healthy Donor NK Cell with Enhanced Anti-Tumor Function and Superior Serial Killing Activity in an Immunosuppressive Environment https://www.editasmedicine.com/wp-content/uploads/2020/12/Editas-ASH_EDIT-201-HDNK.pdf
Preclinical data (ASH) https://ashpublications.org/blood/article/136/Supplement%201/8/472826/Generation-of-Natural-Killer-Cells-with-Enhanced https://ashpublications.org/blood/article/136/Supplement%201/6/472823/Efficient-Gene-Editing-of-CART-Cells-with-CRISPR https://ashpublications.org/blood/article/136/Supplement%201/33/471161/Preclinical-Development-of-Edit-201-a-Multigene
Data at SITC. The poster is: Preclinical Development of EDIT-201, a Multiplexed CRISPR-Cas12a Gene Edited Healthy Donor Derived NK Cells Demonstrating Improved Persistence and Resistance to the Tumor Microenvironment
NEWS: $EDIT 4 Modern Healthcare Stocks Google is Investing In
Google (GOOG) is a tech conglomerate. Its Search business gives it special insight into future trends. So, it's interesting that it's aggressively investing in so many health care companies. Editas (EDIT), American Wellness (AMWL), 1Life (ONEM), and Clover Health (IPOC) are four stocks that i...
Read the whole news EDIT - 4 Modern Healthcare Stocks Google is Investing In
An IND won't be filed until next year (2H). All we know is that the allo NK cells will be expanded using BINATE (feeder-free) tech from Sandhill Therapeutics and both TGFBR2 and CISH will be knocked out by Cas12a.
Today might be the DAY